Publications
- Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice2007 | First Faculty of Medicine
- Anti-tumour resistance in mice treated with HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin +1Publication without faculty affiliation
- HPMA-based doxorubicin conjugate containing human intravenous immunoglobulins shows anticancer effect and protection of immunityPublication without faculty affiliation
- A poly-HPMA-based cytotoxic drug containing human immunoglobulin studied in mouse models: development of antitumour protectionPublication without faculty affiliation
- Treatment with polymer-based doxorubicin conjugate containing human immunoglobulin directed to long-lasting tumour protectionPublication without faculty affiliation
- Anti-tumour efficacy of the conjugate based on N-(2-hydroxypropyl)methacrilamide containing doxorubicin and normal human immunoglobulinPublication without faculty affiliation
- Immunological activity of HPMA copolymer-bound doxorubicin containing human immunoglobulin: experimental and clinical data.Publication without faculty affiliation
- New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting2008 | First Faculty of Medicine
- Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting2008 | First Faculty of Medicine
- Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8(+) T-Cell-Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin2008 | First Faculty of Medicine
Loading network view...